Skip to content
Open access

Early discontinuation of dual antiplatelet therapy after PCI in patients at high bleeding risk: an OCT-guided clinical case

Aug 2026 · Translational Medicine · 0 citations · 16 references

TL;DR

The application of OCT for the evaluation of stent strut endothelialization provides a robust rationale for shortening DAPT duration to 1 month in patients with high hemorrhagic risk, even in the presence of concomitant diabetes mellitus and multiple comorbidities.

Abstract

Background. Optimizing the duration of dual antiplatelet therapy (DAPT) after percutaneous coronary intervention (PCI) remains challenging, especially in patients with high bleeding risk and diabetes mellitus, where stent thrombosis risk is significantly increased due to delayed endothelialization. Objective. To demonstrate the safety of early DAPT discontinuation based on individual assessment of stent endothelialization using optical coherence tomography (OCT). Materials and Methods. We present a clinical case of a 71-year-old female with type II diabetes, atrial fibrillation (CHA2DS2-VASc score of 6), functional class II exertional angina, and a history of left anterior descending (LAD) artery stenting. Risk stratification indicated a high hemorrhagic status: HAS-BLED score of 3, PRECISE-DAPT score of 17, ARC-HBR score of 2, and a CRUSADE score of 49 (corresponding to an 11.9 % risk of major bleeding). Baseline OCT revealed significant narrowing: the minimal lumen area in the LAD was 3.51 mm² (56 % area stenosis), and 2.08 mm² in the right coronary artery (RCA) (72 % area stenosis). Stenting of LAD and right coronary artery was performed using amphilimus-eluting polymer-free stents. DAPT discontinuation was planned at 1 month contingent on sufficient endothelialization per control OCT. Results. Follow-up OCT at one month demonstrated neointimal coverage of 81.18 % of the struts in the LAD and 95.9 % in the RCA. No evidence of stent thrombosis or restenosis was observed. The patient was transitioned to clopidogrel monotherapy, alongside ongoing anticoagulant therapy for the prevention of thrombotic complications associated with atrial fibrillation. During the one-year follow-up period, no ischemic or hemorrhagic adverse events were registered, and there was no recurrence of angina symptoms. Conclusion. The application of OCT for the evaluation of stent strut endothelialization provides a robust rationale for shortening DAPT duration to 1 month in patients with high hemorrhagic risk. This strategy minimizes bleeding threats without escalating the incidence of ischemic events, even in the presence of concomitant diabetes mellitus and multiple comorbidities.

Read PDF

Similar papers

Sep 2026

Single vs. dual antiplatelet therapy in elderly or HBR patients undergoing percutaneous interventions with drug-coated balloons: design and rationale of PICCOLETO IV-EPIC 38 study.

RATIONALE Elderly patients with obstructive coronary artery disease (CAD) frequently present a high bleeding risk (HBR). In this category of patients, percutaneous coronary intervention (PCI) is also associated with a higher risk of periprocedural and long-term ischemic and bleeding complications. PCI with drug-coated...

W. Wańha, S. Iwańczyk, J. M. de la Torre Hernández et al. · 0 citations
Open access Sep 2026

Impact of stepwise dual antiplatelet therapy de-escalation in patients with multivessel disease undergoing drug-coated balloon angioplasty: insights from the REC-CAGEFREE II trial

Among patients with ACS undergoing DCB-only angioplasty, those with multivessel disease were associated with a higher risk of NACE than those with single-vessel disease and stepwise DAPT de-escalation and standard DAPT exhibited similar risk-benefit profiles in both subgroups.

C. Gao, Y. Zhang, X. He et al. · 0 citations
Oct 2026

Low-dose prasugrel versus clopidogrel for dual antiplatelet therapy after percutaneous coronary intervention: insights from the STOPDAPT-2 total cohort.

No significant differences were detected in short-term cardiovascular or bleeding outcomes between low-dose prasugrel-based and clopidogrel-based DAPT in patients after PCI without major in-hospital complications.

T. Isawa, Hirotoshi Watanabe, Takeshi Morimoto et al. · 0 citations
Aug 2026

Clopidogrel or Dual Antiplatelet Therapy in High-Ischemic-Risk Patients.

Among patients at high risk for ischemic events 12 months after drug-eluting stent implantation, clopidogrel monotherapy was noninferior to extended DAPT with respect to net adverse clinical events at 24 months.

Seung-Jun Lee, Yong-Joon Lee, Kyounghoon Lee et al. · 0 citations
Review Open access Aug 2026

Navigating Ischemic and Bleeding Risks in High Bleeding Risk Patients Undergoing Coronary Intervention

A standardized whole-process management framework for HBR patients undergoing PCI is constructed, incorporating 2024–2026 cutting-edge evidence on ultra-short DAPT stratification strategies, gene-guided antiplatelet therapy adjustment, and novel factor XI (FXI) inhibitor antithrombotic regimens, further refining the in...

Ke-Qiang Xu, Lun-Hua Shen, Peng-Fei Xia et al. · 0 citations
Review Aug 2026

Early Aspirin Discontinuation vs 12-Month Dual Antiplatelet Therapy after Percutaneous Coronary Intervention for Acute Coronary Syndrome: A Meta-Analysis of Randomized Trials.

Findings show net benefit of following early aspirin discontinuation strategy due to reduction in major bleeding events without jeopardizing ischemic outcomes are shown.

Abhigna Kolupoti, E. Itaya, Bryan O. Perez Martinez et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.